 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MALVERN, Pa., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...

Ocugen CEO to Present at NobleCon19   Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Ocugen announces first patient dosed in Phase 1/2 trial of OCU410ST

MALVERN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. ( Ocugen or the Company ) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST Modifier Gene Therapy for Stargardt Disease

Conference Call and Webcast Today at 8:30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed...

Ocugen Provides Business Update with Third Quarter 2023 Financial Results

OCGN earnings call for the period ending September 30, 2023...

Ocugen (OCGN) Q3 2023 Earnings Call Transcript

Ocugen, Inc. (OCGN) Q3 2023 Earnings Call Transcript...

Ocugen, Inc. (OCGN) Q3 2023 Earnings Call Transcript

MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...

Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit

MALVERN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...

Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results

NIAID is conducting early phase clinical trials on select next generation vaccine candidates with the intent to identify the most effective platforms and delivery routesOCU500 will be tested as both...

Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

MALVERN, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...

Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Watchers	153,504
52-Wk Low	$0.345
52-Wk High	$1.62

Market Cap	$101.11M
Volume (M)	20,622.00
52-Wk High	$1.62
52-Wk Low	$0.345

OCGN Ocugen Inc

About

Feed

News

Sentiment

Earnings

Fundamentals